SCHEMBL6320773

SCHEMBL6320773

O=C1Cc2c(cccc2-c2cccc(C(=O)O)c2)N1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 4/20 0.55
GSK3B P49841 2/20 0.53
CCNB2 O95067 1/20 0.53
CDK1 P06493 1/20 0.53
CCNB1 P14635 1/20 0.53
CCNB3 Q8WWL7 1/20 0.53
ABL1 P00519 1/20 0.48
BRD4 O60885 4/20 0.46
CREBBP Q92793 3/20 0.46
FOLH1 Q04609 2/20 0.45
KMO O15229 1/20 0.45
CRBN Q96SW2 1/20 0.44
PIP4K2A P48426 1/20 0.44
PIP4K2B P78356 1/20 0.44
GSK3A P49840 1/20 0.44
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
PIM1 P11309 1/20 0.44
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320733 0.84 CRBN (0.65) TDP2GSK3BCCNB2CDK1CCNB1
SCHEMBL5830722 0.84 PIP4K2A (0.56) TDP2GSK3BCCNB2CDK1CCNB1
SCHEMBL6328529 0.82 BRD4 (0.54) TDP2GSK3BCCNB2CDK1CCNB1
SCHEMBL5843496 0.82 JAK2 (0.51) GSK3BCCNB2CDK1CCNB1CCNB3
SCHEMBL6324550 0.80 GRIN2D (0.46) GSK3BCCNB2CDK1CCNB1CCNB3
SCHEMBL16090379 0.79 BRD4 (0.52) TDP2GSK3BCCNB2CDK1CCNB1
SCHEMBL6321593 0.78 TDP2 (0.52) TDP2GSK3BCCNB2CDK1CCNB1
SCHEMBL6319680 0.78 PGR (0.58) TDP2GSK3BCCNB2CDK1CCNB1
SCHEMBL155873 0.78 GSK3B (0.50) TDP2GSK3BCCNB2CDK1CCNB1
SCHEMBL10712645 0.78 TDP2 (0.52) TDP2GSK3BCCNB2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 TDP2 1952/4885GSK3B 81/4885CCNB2 694/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 TDP2 1952/4885GSK3B 81/4885CCNB2 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.